GLP-1s work best in teens with lifestyle support

Clinical takeaway: When prescribing an obesity drug for an adolescent, plan to provide it with structured lifestyle support. This combination was tied to the largest weight reductions, with even basic counseling alongside a drug outperforming the medication alone.

Lifestyle treatment has long been the foundation of pediatric obesity care, but as GLP-1s and other medications reach younger patients, how best to combine the two has been unclear. A new network meta-analysis pooling 42 randomized trials offers the first integrated comparison of drugs, structured lifestyle programs, and their combinations in children and teens. The combinations came out on top, with every medication tied to larger BMI reductions when paired with lifestyle support than when used alone. Structured lifestyle treatment by itself still outperformed any drug given solo.

US guidelines back both structured lifestyle treatment and obesity medications for adolescents, and some medications are now FDA-approved for ages 12 and up. Yet the intensive lifestyle programs shown to work best are out of reach for many families, limited by cost, distance, and staffing. That gap raises a practical question for US clinicians: how do drugs and lifestyle care compare, and does pairing them help?

Every medication was tied to larger BMI reductions when paired with lifestyle treatment than when used alone across the pooled analysis. Lifestyle treatment here meant structured, multicomponent programs; the most intensive, at 26 or more contact hours, performed best.

GLP-1 receptor agonists alone showed no significant BMI reduction, but paired with structured lifestyle treatment they ranked among the top-performing options. The same pattern held for metformin, which was not significantly tied to BMI reduction on its own yet became one of the strongest performers when combined with lifestyle treatment. Even pairing a drug with low-intensity counseling outperformed the drug alone.

Among GLP-1 combinations, semaglutide plus counseling was associated with the largest BMI reduction of any intervention, though that estimate came from a single small trial. Liraglutide and exenatide, the GLP-1s with more pediatric data here, also performed better paired with lifestyle support than alone.

Structured lifestyle treatment on its own was tied to meaningful BMI reductions that exceeded those of any single drug used as monotherapy. It was also the only approach linked to fat-mass loss while preserving lean mass; some medications, including metformin and exenatide, were tied to modest lean-mass loss. Intensive programs outperformed standard ones.

The analysis pooled 42 randomized trials involving 3,835 children and adolescents aged 10 to 19 with obesity. All trials enrolled patients with obesity though some GLP-1 data came from trials treating type 2 diabetes rather than obesity, where dosing and goals differ. The GLP-1s studied were liraglutide, semaglutide, dulaglutide, and exenatide; tirzepatide, a newer dual GIP/GLP-1 receptor agonist, was not included. Most trials ran 6 to 12 months.

The data suggest pairing medication with lifestyle support, at whatever intensity is feasible, rather than using a drug on its own, an approach that fits the reality of very limited access to intensive programs. Intensive lifestyle treatment also stood out on body composition, the approach most consistently tied to fat loss with lean-mass preserved.

"Medications should never be prescribed in isolation; a person-centered, family-centered approach matching treatment intensity to medical need is essential," the authors conclude.

Source: Wan KW, et al. JAMA Pediatr. 2026 Jun 22. Obesity management pharmacotherapies and lifestyle treatment for pediatric obesity